A simple method of quantifying chemotherapy‐induced peripheral neuropathy using PainVision PS‐2100®

This study aimed to validate a simplified method of quantifying chemotherapy‐induced peripheral neuropathy using the PainVision PS‐2100® (PV) electrical perception system.

[1]  N. Staff,et al.  Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  E. Basch,et al.  The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events , 2018, Journal of Patient-Reported Outcomes.

[3]  M. Kashiwaba,et al.  Objective evaluation of chemotherapy-induced peripheral neuropathy using quantitative pain measurement system (Pain Vision®), a pilot study , 2017, Journal of Pharmaceutical Health Care and Sciences.

[4]  M. Dolan,et al.  Chemotherapy-induced peripheral neuropathy: Current status and progress. , 2016, Gynecologic oncology.

[5]  Y. Yamashita,et al.  Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy , 2015, SpringerPlus.

[6]  Gillian L. Currie,et al.  Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis , 2014, PAIN®.

[7]  C. Loprinzi,et al.  Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. , 2014, Journal of oncology practice.

[8]  F. Mols,et al.  Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review , 2014, Supportive Care in Cancer.

[9]  T. Postma,et al.  Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Aaronson,et al.  Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire , 2013, Quality of Life Research.

[11]  J. Heimans,et al.  The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. , 2013 .

[12]  G. Altavilla,et al.  The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Joseph O. Deasy,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .

[14]  勝俣 範之.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomised controlled trial , 2011 .

[15]  Alexia Iasonos,et al.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. , 2009, Journal of the National Cancer Institute.

[16]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[17]  F. Lieberman,et al.  Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. , 2006, Seminars in oncology.

[18]  J. Thigpen.  Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma , 2006 .

[19]  Alex Sparreboom,et al.  Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. , 2006, European journal of cancer.

[20]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[21]  A. Peters.  The effects of normal aging on myelin and nerve fibers: A review , 2002, Journal of neurocytology.

[22]  Alan Peters,et al.  Effects of aging on myelinated nerve fibers in monkey primary visual cortex , 2000, The Journal of comparative neurology.

[23]  F. Ando,et al.  Age and gender differences in skin sensory threshold assessed by current perception in community-dwelling Japanese. , 2000, Journal of epidemiology.

[24]  M. Xi,et al.  Changes in the axonal conduction velocity of pyramidal tract neurons in the aged cat , 1999, Neuroscience.

[25]  B R Goldspiel,et al.  Paclitaxel (Taxol) , 1994, Pharmacotherapy.